Select Page

Press

  • EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine

    EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine

    Posted on October 31, 2022 by Riley Nolan
    EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine PROVIDENCE, RI, October 31, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce participation in a new project with Intravacc, funded by CEPI (Coalition for Epidemic Preparedness Innovations), to develop universal vaccines for betacoronaviruses, including SARS-CoV-2. EpiVax will be carrying out the vaccine epitope ...
    Read more
  • EpiVax Secures Additional Funding from FDA for Immunogenicity Risk Assessment for Biosimilar Products

    EpiVax Secures Additional Funding from FDA for Immunogenicity Risk Assessment for Biosimilar Products

    Posted on September 12, 2022 by Riley Nolan
    PROVIDENCE, RI, September 12, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce the award of a two-year, $2 million grant from the FDA’s Office of Center for Drug Evaluation and Research (CDER) to validate a method for immunogenicity risk assessment of host cell proteins (HCP) for improving biosimilar product development and assessing product ...
    Read more
  • EpiVax Poxvirus Vaccine Candidate Predicted to be Effective Against Monkeypox

    EpiVax Poxvirus Vaccine Candidate Predicted to be Effective Against Monkeypox

    Posted on June 10, 2022 by Riley Nolan
    PROVIDENCE, RI, June 10, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces that it has developed VennVax, a smallpox vaccine candidate that is predicted to be highly effective against monkeypox. The development of this vaccine was funded by the National Institutes of Health (SBIR grant #R43AI058376). The company is looking for a strategic partner with funding ...
    Read more
  • EpiVax and Massachusetts General Hospital Advance on T cell-Targeted Epitope Vaccine for Q Fever

    EpiVax and Massachusetts General Hospital Advance on T cell-Targeted Epitope Vaccine for Q Fever

    Posted on May 25, 2022 by Riley Nolan
    PROVIDENCE, RI, May 25, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models of Coxiella burnetii Immunity” in Frontiers in Immunology, a collaboration with Massachusetts General Hospital’s (“MGH”) Vaccine and Immunotherapy Center, the Oxford Vaccine Group, Colorado State University, and Innatoss ...
    Read more
  • EpiVax Partners with Rhode Island Foundation to Expand Charitable Giving Programs

    EpiVax Partners with Rhode Island Foundation to Expand Charitable Giving Programs

    Posted on February 8, 2022 by Riley Nolan
    PROVIDENCE, RI, February 8, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the establishment of the Vax Gives Back Fund at the Rhode Island Foundation, a step to continue the strong tradition of corporate responsibility and community service at the company. EpiVax has a long standing commitment to charitable giving since the company’s inception in 1998. Dr. ...
    Read more
  • EpiVax Progresses on a Vaccine to Address SARS-CoV-2 Variants

    EpiVax Progresses on a Vaccine to Address SARS-CoV-2 Variants

    Posted on November 30, 2021 by Riley Nolan
    PROVIDENCE, RI, November 30, 2021 /PRNewswire/ — Today EpiVax, Inc. (“EpiVax”) confirmed that the company’s EPV-CoV-19 vaccine epitope sequences are 98.2% conserved in the new Omicron SARS-CoV-2 variant. EpiVax and EpiVax Therapeutics, Inc. (“EVT”) are also affirming commitment to move the novel T cell epitope vaccine into the clinic in 2022. EPV-CoV-19, is intended for ...
    Read more
  • EpiVax Collaborates with Leidos on Malaria Vaccine Research, Series of Papers Published in Frontiers In Immunology

    EpiVax Collaborates with Leidos on Malaria Vaccine Research, Series of Papers Published in Frontiers In Immunology

    Posted on November 17, 2021 by Riley Nolan
    PROVIDENCE, RI, November 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication of three papers focusing on malaria vaccine efficacy, part of a collaboration with Leidos, the University of Georgia Center for Vaccines and Immunology, the University of Oxford’s Jenner Institute, and Sanofi Pasteur’s VaxDesign Campus.  The work was supported by the Office of Infectious ...
    Read more
  • EpiVax Licenses Tregitope Technology to Maruho Co., Ltd. for development of Tregitope-based Therapies to Treat Autoimmune Condition

    EpiVax Licenses Tregitope Technology to Maruho Co., Ltd. for development of Tregitope-based Therapies to Treat Autoimmune Condition

    Posted on November 4, 2021 by Riley Nolan
    EpiVax Licenses Tregitope Technology to Maruho Co., Ltd. for development of Tregitope-based Therapies to Treat Autoimmune Condition
    Read more
  • Immunogenicity Expert and FDA Alum Dr. Amy Rosenberg Joins EpiVax

    Immunogenicity Expert and FDA Alum Dr. Amy Rosenberg Joins EpiVax

    Posted on July 6, 2021 by Riley Nolan
    PROVIDENCE, RI, July 6, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce that Dr. Amy Rosenberg is leaving the FDA’s Division of Therapeutic Proteins, CDER, which she led for over 20 years, to join EpiVax as Senior Director of Immunology and Protein Therapeutics. Dr. Rosenberg’s work has focused on immune tolerance induction and immunogenicity. ...
    Read more
  • EpiVax Identifies T cell Epitopes critical to robust T cell immune response in SARS-CoV-2 , Results Published in NPJ Vaccines

    EpiVax Identifies T cell Epitopes critical to robust T cell immune response in SARS-CoV-2 , Results Published in NPJ Vaccines

    Posted on May 17, 2021 by Riley Nolan
    PROVIDENCE, RI, May 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation” in NPJ Vaccines. This research identifies peptide epitopes associated with T cell immunity to SARS-CoV-2 and confirms that recovering patients produce a memory immune response to iVAX-predicted ...
    Read more
  • Improving Cancer Survival Prediction:  A New Approach with EpiVax Therapeutics’ Ancer Platform

    Improving Cancer Survival Prediction: A New Approach with EpiVax Therapeutics’ Ancer Platform

    Posted on May 13, 2021 by Riley Nolan
    PROVIDENCE, RI, May 13, 2021 /PRNewswire/ — EpiVax Therapeutics, Inc. (“EVT”) announces the publication “Multi‑step screening of neoantigens’ HLA and TCR‑interfaces improves prediction of survival” in Scientific Reports. This study demonstrates a superior method of survival analysis for cancer patients using EVT’s Ancer platform. EVT spun-off from EpiVax, Inc. in 2017 to apply EpiVax tools ...
    Read more
  • EpiVax Demonstrates Antigen-Specific Tolerance Induction in Allergy with Tregitopes, Results Published in Frontiers in Immunology

    EpiVax Demonstrates Antigen-Specific Tolerance Induction in Allergy with Tregitopes, Results Published in Frontiers in Immunology

    Posted on April 27, 2021 by Riley Nolan
    PROVIDENCE, RI, April 27, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs” in Frontiers in Immunology. This research highlights Tregitopes as a promising therapy for allergy. Administration of IgG-derived Tregitopes were found to induce suppressive antigen-specific T-regulatory cells in ovalbumin (OVA) and ragweed-allergic murine ...
    Read more
  • EpiVax Announces Participation in International Consortium for Development of Next-Generation Influenza Vaccines (INDIGO)

    EpiVax Announces Participation in International Consortium for Development of Next-Generation Influenza Vaccines (INDIGO)

    Posted on February 17, 2021 by Riley Nolan
    PROVIDENCE, RI, February 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) today announces its participation in the INDIGO consortium – a partnership of public and private research and development organizations from the EU, India, and United States (funded by the EU and India) with the aim of developing next-generation influenza vaccines with better responsiveness, lower costs, ...
    Read more
  • EpiVax and EpiVax Therapeutics Advance COVID-19 Vaccine Program, EPV-CoV-19

    EpiVax and EpiVax Therapeutics Advance COVID-19 Vaccine Program, EPV-CoV-19

    Posted on December 31, 2020 by Annie De Groot
    PROVIDENCE, R.I., Dec. 31, 2020 /PRNewswire/ — EpiVax (“EpiVax”) and EpiVax Therapeutics (“EVT”) today provide an update on the advancement of their peptide-based COVID-19 vaccine, EPV-CoV-19. EPV-CoV-19, a T cell epitope-based vaccine designed by EpiVax’s scientists in February 2020 and licensed to EVT in August 2020, has completed IND-enabling preclinical validation studies and is making steady progress towards a clinical trial, anticipated in ...
    Read more
  • EpiVax Advances “PANDA” Peptide Therapeutic Immunogenicity Screening Program

    EpiVax Advances “PANDA” Peptide Therapeutic Immunogenicity Screening Program

    Posted on December 29, 2020 by Annie De Groot
    PROVIDENCE, R.I., Dec. 29, 2020 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) today provides an update on the advancement of the company’s peptide therapeutic immunogenicity assessment program. The PANDA (Peptide Abbreviated New Drug Application) immunogenicity assessment program was originally developed for screening generic peptide drugs and their impurities following the publication of the ANDA draft guidance by the Food and Drug Administration ...
    Read more

Join our newsletter

We strive to provide our clients, collaborators and everyday immunology enthusiasts with valuable content.  Written by our CEO/CSO Dr. Anne Dr Groot, you can expect up to date vaccine development efforts, upcoming events and so much more from our offices here in Providence, RI.

Click Here